Company Overview and News
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BAMGF H BRLXF NPIFF BAMKF HRNNF BAM TERP NPI
There are compelling reasons to pick your own stocks here, but this requires more discipline and honesty than when buying an exchange traded fund.
TTTGF FXFLF FXFHF FAXXF MEQYF FRFHF FRFFF MRCBF FRFZF GCM.WT.A FAXRF FRFXF AOCIF BAM CDPYF BAMGF TPWRF VRRKF FRFGF TPRFF MIC GMICF GCM BAMKF TTR
Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Second Quarter Conference Call & Webcast on Thursday, August 9, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives.
BAMGF BAMKF BAM
Eighteen months into Jared Kushner’s White House tenure, his family’s real estate firm is deepening its financial relationships with institutions and individuals that have a lot riding on decisions made by the federal government.
BAMGF NYTAB BAMKF BAM
BROOKFIELD NEWS, July 11, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Business Partners’ (TSX:BBU.UN) (NYSE:BBU) 2018 Second Quarter Conference Call & Webcast on Friday, August 3, 2018 at 9:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives.
BAMGF BBU BAMKF BAM
Mumbai: Canadian alternative assets manager Brookfield Asset Management is in talks with shareholders of Mumbai-based Altico Capital to acquire a significant stake in the non-banking financial company (NBFC), two people aware of the development said on condition of anonymity. According to the people cited above, the proposed investment will be a mix of primary and secondary investment, and may lead to the exit of Varde Partners, one of the shareholders in Altico.
BAMGF ICICIBANK 532174 IBN BAMKF BAM SBAZ
Brookfield Infrastructure Partners has crushed most other utilities and the S&P 500 over the past decade.
BAMGF ENBBF ENB 532712 NEE.PRI ENB BRK.A NEE.PRJ RCOM NEE.PRC NEE.PRQ NEE.PRR EBBNF BIP BAMKF BAM NEE
(Reuters) - Canada’s main stock index edged higher on Friday as financial stocks gained after a strong domestic jobs data cemented expectations of fourth interest rate hike of the year next week.
BAMGF RCI ACBFF TCLAF CG CGEAF TCLCF CGC BCE CAGDF RCIAF TWMJF ACB WEED BAMKF BAM
TORONTO, July 4 (Reuters) - Canada’s main stock index edged higher on Wednesday, helped by gains for heavily-weighted financial shares and Enbridge Inc after the company said it would sell natural gas assets.
BAMGF ENBBF KML ACBFF ENB NMKEF ENB ACB NMX BDRPF EBBNF BIP BAMKF BAM
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
6h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET